Four years after the beginning of the COVID-19 pandemic, it is important to reflect on the events that have occurred during that time and the knowledge that has been gained. The response to the pandemic was rapid and highly resourced; it was also built upon a foundation of decades of federally funded basic and applied research. Laboratories in government, pharmaceutical, academic, and non-profit institutions all played roles in advancing pre-2020 discoveries to produce clinical treatments. This perspective provides a summary of how the development of high-throughput screening methods in a biosafety level 3 (BSL-3) environment at Southern Research Institute (SR) contributed to pandemic response efforts. The challenges encountered are described, including those of a technical nature as well as those of working under the pressures of an unpredictable virus and pandemic.
A high-throughput response to the SARS-CoV-2 pandemic.
针对SARS-CoV-2疫情的高通量应对措施
阅读:8
作者:Rasmussen Lynn, Sanders Shalisa, Sosa Melinda, McKellip Sara, Nebane N Miranda, Martinez-Gzegozewska Yohanka, Reece Andrew, Ruiz Pedro, Manuvakhova Anna, Zhai Ling, Warren Brooke, Curry Aliyah, Zeng Qinghua, Bostwick J Robert, Vinson Paige N
| 期刊: | SLAS Discovery | 影响因子: | 2.700 |
| 时间: | 2024 | 起止号: | 2024 Jul;29(5):100160 |
| doi: | 10.1016/j.slasd.2024.100160 | 研究方向: | 炎症/感染 |
| 疾病类型: | 新冠 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
